Japan became the first country to approve the anti-viral influenza drug Rapiacta (peramivir) that is licensed by Shionogi & Co., Ltd. from UK-based BioCryst Pharmaceuticals, the Nikkei Sangyo Shimbun reported in January.
The intravenous drip infusion drug is easily administered to aged or critically ill patients for influenza A and B virus strains.
